Emergent BioSolutions Inc.
Emergent BioSolutions Reports Financial Results for First Quarter 2008
Published in Medical Letter on the CDC and FDA, May 25th, 2008
Total revenues for the first quarter of 2008 grew 62 percent to $42.7 million from $26.4 million in 2007, primarily from growth in sales of BioThrax(R) (Anthrax Vaccine Adsorbed). Net income for the first quarter of 2008 was $7.0 million, or $0.24 per share, in comparison to a net loss of $2.7 million, or $0.10 per share, for the comparable period in 2007.
R. Don Elsey, Emergent BioSolutions' chief financial officer, said, "Our first quarter 2008 financial performance reflects the continued strength of our business approach of generating...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Society for General Microbiology
Scientists discover why plague is so lethal - Alzheimer Disease
Studies from University of Washington in the area of Alzheimer disease described - Drug Development
Study data from University of Rochester update knowledge of drug development - Life Sciences
Research results from K.C. Wood and co-authors update knowledge of life sciences - Life Sciences
Researchers from Food & Drug Administration discuss findings in life sciences - Smoking
New Evidence Provides Clinicians With Better Tools to Help Smokers Quit - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
